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Abstract
Background
Many patients with malaria-like symptoms seek treatment in private medicine retail outlets
(PMR) that distribute malaria medicines but do not traditionally provide diagnostic services,
potentially leading to overtreatment with antimalarial drugs. To achieve universal access to
prompt parasite-based diagnosis, many malaria-endemic countries are considering scaling
up malaria rapid diagnostic tests (RDTs) in these outlets, an intervention that may require
legislative changes and major investments in supporting programs and infrastructures. This
review identifies studies that introduced malaria RDTs in PMRs and examines study out-
comes and success factors to inform scale up decisions.
Methods
Published and unpublished studies that introduced malaria RDTs in PMRs were systemati-
cally identified and reviewed. Literature published before November 2016 was searched in
six electronic databases, and unpublished studies were identified through personal contacts
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and stakeholder meetings. Outcomes were extracted from publications or provided by prin-
cipal investigators.
Results
Six published and six unpublished studies were found. Most studies took place in sub-
Saharan Africa and were small-scale pilots of RDT introduction in drug shops or pharma-
cies. None of the studies assessed large-scale implementation in PMRs. RDT uptake
varied widely from 8%-100%. Provision of artemisinin-based combination therapy (ACT)
for patients testing positive ranged from 30%-99%, and was more than 85% in five stud-
ies. Of those testing negative, provision of antimalarials varied from 2%-83% and was
less than 20% in eight studies. Longer provider training, lower RDT retail prices and fre-
quent supervision appeared to have a positive effect on RDT uptake and provider adher-
ence to test results. Performance of RDTs by PMR vendors was generally good, but
disposal of medical waste and referral of patients to public facilities were common
challenges.
Conclusions
Expanding services of PMRs to include malaria diagnostic services may hold great promise
to improve malaria case management and curb overtreatment with antimalarials. However,
doing so will require careful planning, investment and additional research to develop and
sustain effective training, supervision, waste-management, referral and surveillance pro-
grams beyond the public sector.
Background
Provision of artemisinin-based combination therapies (ACTs) and other antimalarials to
patients without confirmed malaria frequently results in overtreatment, potentially delaying
diagnosis and treatment of other causes of illness and reducing availability of ACTs for true
malaria cases [1, 2]. Overuse of antimalarials by patients without malaria has been estimated to
be half of global demand [3].
Prompted by recommendations from the World Health Organization in 2010 [4], national
malaria programs in most endemic countries revised their diagnosis and treatment guidelines
to emphasize the use of parasite-based diagnosis of malaria before treatment for all suspected
malaria cases [5, 6]. Since then, procurement of malaria rapid diagnostic tests (RDTs) has
increased significantly in the public health care sector across much of sub-Saharan Africa [5,
7]. In contrast, availability and use of diagnostic testing in the private medicine retail sector
has remained low. Efforts to improve or expand malaria case management in the private sec-
tor, as demonstrated in the Affordable Medicines Facility- malaria (AMFm) pilot, focused on
treatment delivery, but did not promote the use of diagnostic testing [8]. Evidence shows that
RDTs or microscopy are available in less than 20% of pharmacies and drug shops selling anti-
malarials in six out of eight sub-Saharan African countries surveyed in 2013 or 2014 [9].
Though treatment-seeking practices vary greatly between countries, overall approximately
one-third of febrile children obtaining malaria drugs are treated by private providers with lim-
ited access to malaria diagnostic services [3].
Introducing malaria RDTs in private medicine retail outlets
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The private health care sector consists of private not-for-profit and private for-profit health
providers, with the latter including private health facilities, diagnostic centers, private medi-
cine retailers and informal practitioners [10]. Private medicine retail outlets (PMRs), a large
category of for-profit private health providers in many countries [11], include outlets that spe-
cialize in medicines such as pharmacies and drug stores, as well as general stores or itinerant
vendors that sell medicines along with other household merchandise [12]. In many countries,
PMRs play a dominant role in the distribution and sale of antimalarials [9]. Typically, the out-
lets that specialize in selling medicines have storefronts, product displays, and a counter. Some
may have a small room in the back, separated by a curtain or door, for examinations and treat-
ment. Skills and qualifications vary among staff working in these outlets and include physi-
cians, pharmacists, nurses and drug sellers with little to no formal health training [13]. PMRs
are allowed to only carry over the counter drugs and in some cases a limited number of pre-
scription drugs such as antimalarials and certain antibiotics. They are typically not allowed to
perform diagnostic services, but government regulations vary amongst countries and are often
poorly enforced [14–16].
Given the importance of PMRs as a first source of care and antimalarial treatment, several
endemic countries in sub-Saharan Africa and Southeast Asia are considering introducing and
scaling up RDTs in these outlets to achieve universal access to prompt parasite based diagnosis
prior to treatment [17]. Introducing blood-testing in these outlets is not without controversy,
and evidence to guide decisions on how and where to scale up RDTs amongst PMRs is cur-
rently lacking [18]. PMRs are often poorly supervised, rarely report into health information
systems and are not equipped to manage severe illnesses [12]. Although the procedure to per-
form RDTs does not require specialized training, operators are required to draw and transfer
an exact quantity of blood, apply a specific number of buffer drops, wait the required time
before a result can be read (i.e. 15 or 20 minutes) and appropriately dispose of the hazardous
infectious waste. Without adequate oversight, public health officials fear that PMRs may misdi-
agnose patients or not treat patients according to malaria guidelines, providing antimalarials
or antibiotics to patients that test negative for malaria [19]. PMRs may also use substandard
RDTs, affecting the trust in the result of the test and hence adherence to its results [20]. There
is also a concern that improper handling of hazardous waste may lead to the spread of other
infectious illnesses [21].
This review identifies and synthesizes available evidence and explores how it can help
inform decisions about scaling up RDTs in PMRs.
Objectives
We undertook a systematic review of published and unpublished intervention studies to evalu-
ate available evidence of the implementation and impact of RDT introduction in PMRs (phar-
macies, drug stores, general stores, and/or itinerant vendors that sell medicines along with
other household merchandise). The review aimed to:
1. Examine outcomes pertaining to RDT uptake, provider adherence to test results, referral,
cost and safety.
2. Review characteristics of each intervention to introduce RDT use (e.g. the length and con-
tent of trainings, supervision frequency, referral guidelines, demand generation activities
and retail price of RDTs) to explore factors that are associated with RDT uptake and pro-
vider adherence to test results.
Introducing malaria RDTs in private medicine retail outlets
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Methods
Registration and eligibility criteria
We followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses
(PRISMA) guidelines (http://www.prisma-statement.org/) and registered with PROSPERO
(2013:CRD42013006146). We used the following inclusion criteria:
• Participants: Any PMR providers and their patients
• Interventions: Any introduction of RDTs with or without supporting interventions, where
RDTs were performed by PMR staff
• Comparisons: Studies were included whether or not there was a comparison group, and
whether or not the comparison group was randomly allocated
• Outcomes: Any measurement of the impact of an intervention to introduce RDTs, such as
RDT uptake, provider adherence to test results, recommended retail price or safety protocols
We excluded studies that took place outside of PMRs among other private for-profit, pri-
vate not-for-profit, and public health care providers (e.g., private health facilities, mission or
non-governmental facilities, community health workers, and public health facilities); that
reported only on the accuracy of RDTs (such as laboratory-based performance comparisons);
where RDTs were not introduced into routine practice (if not performed by outlet staff or
used only for reference by a research team); that evaluated the use, presence or proportion of
outlets stocking RDTs without implementing any interventions to introduce RDTs; and stud-
ies based on hypothetical scenarios or modeling. To increase the evidence base, recent studies
yet to be published at the time of the search were also included in the review. Principal investi-
gators from unpublished studies were asked to extract specific testing and treatment outcome
data to enable analysis across studies. Principal investigators of published studies were also
asked to provide clarifications and data on additional outcomes not reported in the
publication.
Search methods
We performed a systematic literature search of electronic databases on November 16, 2016,
including PubMed/Medline, Cochrane Library Online, WHOLIS internet databases, IBSS,
Web of Science and Ovid (EMBASE, Global Health, and Journals at Ovid). Studies which were
yet to be published were identified at a Roll Back Malaria (RBM) Case Management Working
Group, Informal Private Sector Task Force meeting in April 2013 [22] and a consultative
working meeting on fever case management in the private health care sector in Africa, orga-
nized by ACT Consortium in October 2015 [17].
Search terms. Literature searches used synonyms and MESH terms for three concepts (i)
‘malaria’ (ii) ‘rapid diagnostic test’ and (iii) ‘private sector’. No search terms or filters for meth-
ods were included. Table 1 provides an overview of the search terms.
Study selection. For published studies the resulting titles and abstracts were reviewed
independently by two authors (TV and KB) to select papers or reports to read in full text. Dis-
crepancies were resolved by a third author (KM). Papers that were clearly irrelevant were
excluded after reading title and abstract. The remaining papers were read in full and excluded
if they did not match the inclusion criteria after agreement between TV, KB and KM. Remain-
ing papers were included in the systematic review.
For inclusion of unpublished studies, investigators were contacted initially to ascertain
whether studies met the eligibility criteria, whether data would be available and/or computed
Introducing malaria RDTs in private medicine retail outlets
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within a given time frame and to reach agreement with investigators to include their unpub-
lished findings in the review. Studies that met each of these criteria were subsequently included
in the review and investigators asked to contribute results from their studies.
Data outcomes and extraction
Data extraction tables were used to collate information from both published and unpublished
studies. The following diagnosis and treatment outcomes were compared across studies:
1. Uptake: the proportion of patients seeking treatment for fever or suspected malaria who
were tested with an RDT
2. RDT positivity: the proportion of patients receiving a positive RDT result
3. ACT provision: the proportion of patients seeking treatment for fever or suspected malaria
who were sold ACTs, regardless of whether or not they were tested
4. Adherence to negative or positive test results: the proportion of patients that were sold
ACTs in the presence of a positive RDT result or the proportion of patients that that were
not sold ACTs or other antimalarials in the presence of a negative RDT result
5. Antibiotic provision: the proportion of patients who were sold antibiotics in the presence of
a positive RDT result; or the proportion of patients who were sold antibiotics in the pres-
ence of a negative RDT result
6. Referrals: the proportion of patients referred to a public facility by the provider for further
care
7. Accuracy and safety: the proportion of PMR providers who accurately performed the RDT,
read the result, and adequately disposed of the infectious hazardous waste
8. Median retail price of a RDT
We reported outcomes as proportions with comparable denominators where possible. In
studies that provided cluster and individual level outcomes, we chose to use individual out-
comes to enable comparison across studies. Where the same outcome was reported by more
than one method of data collection, we chose the most complete data set, or presented neither
if results for an outcome substantially differed between methods. To explore factors that
appear to have supported RDT uptake and provider adherence to test results, outcomes across
study arms were reviewed in terms of the characteristics of each intervention (length and con-
tent of trainings, supervision frequency, demand generation activities, recommended RDT
retail price and referral policy). We did not make statistical comparisons between studies
because of the different methodologies and outcomes used.
Table 1. Search terms.
Malaria Malaria+
Diagnosis rapid diagnostic test+, RDT+, diagnose, diagnosis, diagnostic+, test+, testing (excludes
laboratory trial, travel+)
Private
sector
private sector+, commerce+, commercial sector, retail sector, private provider, private
providers, drug seller, drug sellers, private outlet, private outlets, drug vendor, drug vendors,
drug shop, drug shops, retailer, retailers, medicine shop, medicine shops, drug store, drug
stores, pharmacy, pharmacies, informal provider, informal providers, patent medicine
vendor, retail+, private, drug retailer+, sale+, over-the-counter, unregulated, shop+, profit,
informal, chemists, private laboratories
doi:10.1371/journal.pone.0173093.t001
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Results
Study selection
A total of 1645 titles from published studies were identified through the search strategy (Fig 1).
After removing duplicates, 904 titles and abstracts were screened and 136 publications were
reviewed in detail. Of these, two studies focused on Cambodia [23, 24], where RDTs had been
scaled-up for over a decade. However, these studies did not directly evaluate the impact of
implementation of RDTs on any outcomes comparable with other studies. Two other studies
Fig 1. Search strategy.
doi:10.1371/journal.pone.0173093.g001
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(Cohen et al. 2012 and Awor et al. 2014) published initial data followed by more recent publi-
cations with additional data from the same studies (Cohen et al. 2015 and Awor et al. 2015).
Each of these pairs are presented together and counted as one study. In addition, eight unpub-
lished studies were identified. Two of these, a study in Madagascar and a study in Angola,
were excluded, as data were not available at the time of this review. In all, six published [25–
32] and six unpublished studies (please refer to the supporting information file S2 File) were
included in the review, for a total of 12 studies.
Study design and characteristics
Table 2 provides characteristics of the included studies. Most were trials of pilot interventions
to introduce RDTs in PMRs specialized in selling drugs (e.g., drug shops or pharmacies) in
sub-Saharan Africa, with one trial in Myanmar (Aung et al. 2015). Four studies had a control
group without RDTs (Ansah et al. 2015; Awor et al. 2013; Maloney et al. under review; Mbonye
et al. 2015) and three studies had multiple RDT intervention arms (Aung et al. 2015; Maloney
et al. under review; Onwujekwe et al. 2015). The studies took place in areas of medium to high
malaria transmission [33] and in rural, peri-urban, and urban settings. Outcomes were
assessed using various data collection methods: provider records, exit interviews, mystery
shoppers, direct observation, supervision visits, and household surveys (Table 3). Regulations
in all study countries except Myanmar did not permit RDTs to be performed by providers in
PMRs; studies were granted waivers or special permission from governments. The length of
the studies ranged from six months (Onwujekwe et al. 2015) to 27 months (Allan et al. unpub-
lished data). The number of outlets where RDTs were introduced varied from 29 to over 600
outlets in the intervention arm in Uganda and Myanmar, respectively (Mbonye et al. 2015,
Aung et al. 2015).
RDTs were either free to patients (Ansah et al. 2015; Awor et al. 2014, 2015) or heavily
subsidized by implementers. Subsidies ranged from US$0.26 to US$0.8 per RDT (Mbonye
et al. 2015; Aung et al. 2015; Streat et al. Zambia unpublished data; Streat et al. Ug unpub-
lished data; Streat et al. Nigeria unpublished data; Allan et al. unpublished data; Onwujekwe
et al. 2015; Cohen et al. 2012, 2015), except in a study in Kenya (Poyer et al. unpublished
results) and one arm of a study in Tanzania (Maloney et al. under review), where RDTs were
not subsidized. Gloves and infectious hazardous waste disposal units (i.e. a sharp box) were
provided free of cost in most studies. RDTs were distributed either directly to a participating
provider from a research warehouse or through a pre-selected wholesaler, importer or gov-
ernment entity. The length of the training varied from half a day to five days and often com-
bined lectures and practice in performing the RDTs. Training content typically covered the
symptoms of malaria and the recommended policies on antimalarial treatment and safety. In
most intervention arms, training emphasized adherence to test results, including guidance
on referral to nearby public health facilities for patients with signs of severe disease. Most
studies also recommended referral when patients tested negative. Exceptions included a
study in Uganda, where providers were trained on ACTs as first-line malaria treatment and
how to perform RDTs but were not given specific algorithms on when to use RDTs or how
to manage positive and negative results (Cohen et al. 2012, 2015). In another study in
Uganda, the RDT introduction was part of a five day integrated community case manage-
ment (iCCM) training that included treatment of malaria, pneumonia, and diarrhoea (Awor
et al. 2014, 2015). In one arm of a study in Nigeria, training focused only on how to perform
RDTs (Onwujekwe et al. 2015). The frequency of supportive supervision also differed, but in
most studies research staff visited participating facilities monthly or quarterly to evaluate
stock management, waste management practices and how RDTs were performed, stored,
Introducing malaria RDTs in private medicine retail outlets
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and priced (through direct observation using a checklist). In a study in Kenya, outlet supervi-
sion visits were conducted based on febrile client volume and quality of care, prioritizing
high volume and under-performing outlets (Poyer et al. unpublished data). In studies in
Nigeria and Uganda, professional associations and medical retailers were contracted to per-
form the supervision (Streat et al. Nigeria unpublished data; Streat et al. Uganda unpublished
data). Activities to raise awareness of RDTs included organizing community meetings and
door to door visits using volunteer health promotors (Allan et al. unpublished data, Mbonye
et al. 2015), community films (Ansah et al. 2015) conducting small group communication
sessions and household visits (Poyer et al. unpublished data), school-based activities (Onwu-
jekwe et al. 2015) and national or regional media campaigns promoting the use of RDTs
(Cohen et al. 2012, 2015; Maloney et al. under review; Poyer et al. unpublished data; Streat
et al. Nigeria unpublished data; Streat et al. Uganda unpublished data).
Table 3. Data collection methods.
Study Outcomes
First
author
Country Uptake Positivity ACT
consumption
Adherence Antibiotic
usage
Referrals Safety &
Accuracy
Retail Price
(% of
treatment
seeking
patients
receiving
RDT)
(% of
patients
receiving an
RDT who
tested
positive)
(% of patients
presenting with
fever who got
an ACT)
(% of those
testing
negative/
positive/not
tested
receiving ACT
or AM)
(% of febrile
patients
testing
positive/
negative
taking
antibiotic)
(% of patients
referred
elsewhere by
the provider
for further
care)
(% of providers
who could
accurately
perform an
RDT/ interpret
results/dispose
of waste)
(Median
retail price
in US$)
Allan Liberia Mystery
shopper
Mystery
shopper
Mystery
shopper
Exit interviews Mystery
shopper
Mystery
shopper
Mystery shopper Mystery
shopper
Ansah Ghana Provider
records
Provider
records
Provider
records
Provider
records
Provider
records
Provider
records
Direct
observations
NA
Aung Myanmar Mystery
shopper
Mystery
shopper
Mystery
shopper
NA NA NA Mystery shopper Mystery
shopper
Awor Uganda Exit
interviews
Exit
interviews
Exit interviews Direct
observations
NA NA NA NA
Cohen Uganda Provider
records
Provider
records
Monthly
household
surveys
Monthly
household
surveys
Monthly
household
surveys
NA Supervision
visits
Supervision
visits
Maloney Tanzania Exit
interviews
Exit
interviews
Exit interviews Exit interviews Exit
interviews
NA Supervision
visits
Supervision
visits
Mbonye Uganda Provider
records
Provider
records
Provider
records
Provider
records
Household
follow up
surveys
Provider
records
Supervision
visits
Household
follow up
surveys
Onwujekwe Nigeria Exit
interviews
Exit
interviews
Exit interviews
and provider
records
Exit interviews
and provider
records
Exit
interviews
and provider
records
Exit
interviews
NA Exit
interviews
Poyer Kenya Exit
interviews
Exit
interviews
Exit interviews Exit interviews Exit
interviews
Exit
interviews
NA Exit
interviews
Streat Nigeria Provider
records and
exit
interviews
Provider
records
NA Provider
records
NA NA Supervision
visits
Exit
interviews
Streat Uganda Exit
interviews
Exit
interviews
Exit interviews Exit interviews NA NA Supervision
visits
Exit
interviews
Streat Zambia Exit
interviews
Exit
interviews
NA Mystery
shopper
Mystery
shopper
NA Mystery shopper Exit
interviews
doi:10.1371/journal.pone.0173093.t003
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Testing and treatment outcomes
Table 4 provides the diagnosis and treatment outcomes included in the review. Table 5 pro-
vides a summary of diagnosis and treatment outcomes by study arm alongside a summary of
the supporting interventions implemented, ordered by RDT uptake (high to low).
Uptake of RDTs. All studies reported on uptake (the proportion of eligible patients for
whom an RDT was undertaken), which ranged from 8% (96/1279, exit interviews) in the pro-
vider and school-based intervention arm of a study in Nigeria (Onwujekwe et al. 2015) to
100% (2719/2719, provider records) in a study in Ghana (Ansah et al. 2015). Five studies
reported uptake below 50% (Cohen et al. 2013, 2015; Streat et al. Uganda unpublished data;
Allan et al. unpublished data; Onwujekwe et al. 2015; Poyer et al. unpublished), three studies
reported uptake between 50% and 80% (Aung et al. 2015; Maloney et al. under review; Streat
et al. Zambia unpublished data) and three studies reported uptake above 80% (Mbonye et al.
2015; Ansah et al. 2015; Awor et al. 2014, 2015).
ACT provision and RDT positivity. Eight studies reported on ACT provision among all
patients seeking treatment for fever or suspected malaria. ACT provision ranged from 30% to
60% in six studies (Allan et al. unpublished data; Ansah et al. 2015; Maloney et al. under
review; Mbonye et al. 2015; Onwujekwe et al. 2015; Poyer et al. unpublished data). Both the
highest ACT provision (81%, 393/487, exit interviews) and the lowest (29%, 840/2868, house-
hold surveys) were reported in studies in Uganda (Awor et al. 2014, 2015 and Cohen et al.
2012, 2015, respectively).
ACT provision was compared between intervention and control (no RDT intervention)
arms in four studies: in Uganda (Mbonye et al. 2015; Awor et al. 2014, 2015), Ghana (Ansah
et al. 2015), and Tanzania (Maloney et al. under review). In three of these studies, 10 to 40 per-
centage points fewer patients in the RDT intervention arms compared to the control arms
obtained ACTs (Mbonye et al. 2015, Ansah et al. 2015; Maloney et al. under review). RDT pos-
itivity in these studies was approximately 50% to 60%. In Awor et al. (2014, 2015), 20 percent-
age points more patients in the intervention arm compared to the control arm obtained ACTs.
In this study, RDT positivity and ACT provision were both high (75% and 81%, respectively).
Four other studies also reported similarly high RDT positivity (Streat et al. Uganda, unpub-
lished data; Streat et al. Zambia, unpublished data; Onwujekwe et al. 2015; Cohen et al. 2012,
2015), while RDT positivity in the remaining studies ranged from 33% to 50% (Ansah et al.
2015; Mbonye et al. 2015; Onwujekwe et al. 2015; Allan et al. unpublished data).
Adherence to RDT results. All studies reported adherence to RDT results. Overall, anti-
malarials were less commonly provided to RDT-negative patients than to RDT-positive and
untested patients. In eight studies, the percentage of RDT-negative patients who received an
unnecessary antimalarial was at or below 20% (Ansah et al. 2015; Awor et al. 2014, 2015; Aung
et al. 2015; Maloney et al. under review; Mbonye et al. 2015; Poyer et al. unpublished data;
Streat et al. Nigeria unpublished data; Streat et al. Uganda unpublished data). However, high
adherence was not universal. A study in Uganda (Cohen et al. 2013, 2015) found relatively low
adherence, with 41% of patients testing negative receiving an antimalarial (22/54 household
members reporting getting an RDT at a drug shop). In addition, all three intervention arms in
a study in Nigeria (Onwujekwe et al. 2015) found very low adherence, with over 50% of those
testing negative receiving an antimalarial.
The proportions of RDT-positive patients receiving ACTs exceeded 85% in six studies
(Ansah et al. 2015; Awor et al. 2014, 2015; Maloney et al. under review; Mbonye et al. 2015;
Poyer et al. unpublished data; Streat et al. Zambia unpublished data). In four studies, ACT pro-
vision ranged between 65% and 85% (Allan et al. unpublished data; one intervention arm of
Maloney et al. under review; Streat et al. Uganda unpublished data; Onwujekwe et al. 2015).
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The lowest adherence to positive results (30%, 128/421, household surveys) was found in a
study in Uganda that also found relatively poor uptake and adherence to negative test results
(Cohen et al. 2012, 2015).
Eight studies reported on antibiotic use. The proportion of RDT-negative patients receiving
antibiotics ranged from 0.3% (6/1854, exit interviews) in a study in Ghana (Ansah et al. 2015)
to 45% (51/113, household survey) in a study in Uganda (Mbonye et al. 2015). Three studies
reported antibiotic use exceeding 20% (Cohen et al. 2012, 2015; Mbonye et al. 2015; Poyer
et al. unpublished data), with the remaining studies reporting below 20%. Similarly, the pro-
portion of patients with a positive RDT result receiving antibiotics varied from 0% (0/1351,
provider records) in Ghana (Ansah et al. 2015) to 31% (129/441, household survey) in a study
in Uganda (Cohen et al. 2012, 2015). Studies that reported relatively high provision of antibiot-
ics to RDT-negative patients also reported high provision to RDT positive patients (Cohen
et al. 2012, 2015; Mbonye et al. 2015; Poyer et al. unpublished data).
Referrals. Only five studies reported on the proportion of patients who were referred to
public hospitals or clinics. In all of these studies, providers were instructed to refer all RDT
negative cases. In a study in Ghana (Ansah et al. 2015), 62% of the 1088 referred patients inter-
viewed by phone reported attendance at the referral facility. The public health facilities had
been made well aware of testing going on in the drug shops and accepted the referred patients.
In the remaining four studies, referrals were 10% or less of the cases. Reasons given for low
rates of referral were explored explicitly in a qualitative component to the study in Uganda
(Mbonye et al. 2015), although investigators in other studies reported similar challenges. Pro-
viders in the Ugandan study were reluctant to refer except when it was considered medically
imperative because of fears that public health workers were unwilling to take patients referred
from drug shops or would question the competence of outlet providers, thereby damaging
their reputations [34]. Vendors were also concerned that clients might go to another shop
rather than to a public facility, and they would lose their clientele. In almost all settings, formal
referral systems from private medicine retail outlets to public facilities had not been estab-
lished. In those studies where providers were encouraged to refer patients with severe illness
or if a clear diagnosis could not be made, there was anecdotal evidence of poor or contradic-
tory treatment at the receiving facility.
Safety & accuracy in performing RDTs. Nine studies provided data on how RDTs were
administered using a check list. In general, most providers were able to accurately perform the
RDT, read its results and dispose of the hazardous infectious waste appropriately. In six studies
where this outcome was recorded, approximately 85% or more of the providers performed the
test safely and correctly (Aung et al. 2015; Ansah et al. 2015; Awor et al. 2014, 2015; Cohen
et al. 2012, 2015; Maloney et al. under review; Mbonye et al. 2015). In studies in Nigeria (Streat
et al. unpublished data) and Uganda (Streat et al. unpublished data) only 75% of providers per-
formed and disposed of the RDT appropriately. A study in Liberia (Allan et al. unpublished
data) found that only 39% (15/38, mystery shoppers) performed all nine of the required steps,
with the most common omissions being not disposing of sharps in a safety box and not waiting
the appropriate amount of time to read the result. Studies in Tanzania (Maloney et al. under
review) and Uganda (Cohen et al. 2012, 2015) found that providers would often not wear
gloves, in addition to the issue of waiting the required number of minutes and adequate dis-
posal of lancets.
Price of test to patient. In the seven studies that used a recommended retail price (RRP),
actual median retail prices matched the RRP in a study in Tanzania (US$0.67 and US$0.32 in
unsubsidized and subsidized arms respectively, Maloney et al. under review) and a study in
Uganda (at a subsidized price of $1, Streat et al. Uganda unpublished results). The actual
observed median retail prices exceeded the RRP in the other five studies, ranging from US
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$0.32 (23% above the RRP) in a study in Liberia (Allan et al. unpublished) to US$1.20 (100%
above the RRP) in a study in Nigeria (Onwujekwe et al. 2015). In a study in Uganda (Cohen
et al. 2012, 2015) that did not use a RRP, most providers priced RDTs to match local micros-
copy prices at US$0.40. The remaining studies either provided RDTs for free (Ansah et al.
2015; Awor et al. 2014, 2015) or for a fixed price of around $0.20 (Mbonye et al. 2015; Streat
et al. Zambia unpublished data).
Discussion
The introduction of RDTs in PMRs, a primary source of care in many settings, aims to
improve case management of febrile illnesses through prompt and appropriate treatment of
malaria and a reduction in delays to diagnosis and treatment of other illnesses. This review
demonstrates that while RDT introduction can achieve this goal, such outcomes are not
guaranteed. Although studies with more intensive interventions generally produced better out-
comes, it is unclear whether such efforts could be maintained or scaled up to national level.
The three studies that showed the highest uptake and the highest adherence (Ansah et al.
2015; Mbonye et al. 2015; Awor et al. 2015) included longer trainings (4 or 5 days), close and
frequent supervision for an initial period of time (weekly visits by the research team), and low
RDT retail prices (US$0.20 or less). These three studies also included the lowest number of
outlets compared to the other studies reviewed.
However, there are notable exceptions to these trends. A study in Nigeria (Onwujekwe
et al. 2015) compared the uptake of RDTs and adherence to national malaria guidelines
under different training scenarios and found that longer and more comprehensive training
(two days covering diagnosis and treatment versus one day with only a demonstration on
how to use RDTs) did not appear to affect uptake or adherence. In contrast, classroom-based
trainings on malaria case management in a study in Myanmar (Aung et al. 2015), were rela-
tively short (only 0.5 days), but uptake and adherence were better than in some studies with
longer trainings. Similarly, in a study in Tanzania (Maloney et al. under review), subsidizing
the retail price of RDTs by over 50% did not increase uptake compared with an unsubsidized
price. Factors that may limit the comparability of outcomes to the intensity of the related
interventions include study setting and context (e.g., prior exposure of provider to malaria
case management training), the timing of the evaluation (e.g., 3 months vs. 12 months after
implementation), the method of data collection (e.g., mystery shopper vs. provider records),
the number of outlets included in the studies (e.g., 18 vs. 1502 outlets) or unique events that
affected study outcomes (e.g., in a study in Nigeria (Streat et al. Nigeria unpublished data),
leakage from public sector into the private sector flooded the market, negatively impacting
the uptake‘of ‘project’ RDTs).
None of the studies deployed interventions that could be scaled-up easily at the national
level. For example, a highly effective intervention in Uganda (Mbonye et al. 2015) included
four day trainings, weekly supervision visits for the first two months and a free, continued sup-
ply of RDTs, gloves and sharp boxes. Studies that implemented less intense but perhaps more
scalable interventions often produced poorer outcomes. For example, in a study in Uganda
(Cohen et al. 2012 2015) that showed low RDT uptake and adherence, PMRs were free to
choose the price at which the RDTs were sold and free to make treatment recommendations as
they wished. Another study, where RDT stock outs were recorded in a study in Tanzania (Mal-
oney et al. under review), chose not to control the supply of RDTs; PMRs were simply
informed where they could procure RDTs. Schools in an intervention arm of a study in Nigeria
(Onwujekwe et al 2015) were supported to organize malaria events to promote uptake and
adherence, but only half of the participating schools did so.
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Heterogeneity in outcomes following RDT introduction is not unique to the private sector
[35–37]. While many public health facilities that increased diagnostic testing for malaria
through the use of RDTs also reported reductions in ACT provision, the availability of RDTs
alone does not seem sufficient to ensure the appropriate use of ACTs [38, 39]. Public and pri-
vate providers alike have rationales for providing antimalarials to patients with a negative RDT
result. Anxiety over the potential for patients to worsen without being given antimalarials
seems paramount [40, 41], just as with antibiotics in other settings [42]. This is accentuated in
contexts where antimalarials are expected, or even demanded, by patients or customers [43],
and where clients can take their business elsewhere [44]. Overstretched providers may find the
time it takes to perform the RDT prohibitive and choose to assist other customers instead of
performing the RDT or waiting for its result [45]. In all sectors, behavior change is likely to
require sustained efforts.
Experience from these studies showed that requirements for introducing RDTs at scale in
PMRs should be viewed as the introduction of a comprehensive service, not just another com-
modity. However, evidence on how to do so remains limited in many operational aspects. First,
evidence is needed on how to integrate malaria testing into case management beyond malaria.
Where negative cases are expected to be referred, this may be challenging: clients have chosen
the retail sector, providers are keen to make a sale, and public sector workers may be unwelcom-
ing to patients referred from PMRs [34]. Guidelines for managing RDT negative adults and chil-
dren require specific development, based on levels of expertise, resource availability, and local
regulations. Second, evidence is needed on how to train and supervise PMRs, given the size and
heterogeneity of the sector as well as rapid staff turnover [13]. It may not be feasible or even
desirable to train and supervise all PMRs. Some studies experimented with innovative supervi-
sion approaches to prioritize certain shops over others based on sales volume or performance
[Poyer et al. unpublished data], but little is understood how to find, select or retain these ‘suc-
cessful’ providers. Some studies in the review [Poyer et al. unpublished data; Streat et al. Nigeria
unpublished data; Streat et al. Uganda unpublished data; Maloney et al. under review] aimed to
provide more sustainable mechanisms (i.e. having professional associations instead of research
team members conduct supervision visits, not subsidizing the RDT or controlling the supply
chain) that could be scaled and exist beyond the length of the study, but scale up was not tested.
New innovative approaches that build on existing structures and programs in the private sector,
rather than building parallel infrastructures, require exploration. Third, evidence is needed on
how to deal with hazardous waste from testing at scale in these non-clinical settings. In most
studies in this review, research teams were responsible for this. One study in Tanzania (Maloney
et al. under review) that instructed providers to visit public health facilities to drop off waste had
mixed success; many providers instead chose to bury or burn their waste. A study in Uganda
(Streat et al. Uganda unpublished data) contracted a private firm to collect the waste at each of
the participating outlets, but poor uptake combined with frequent collection visits caused cost
overruns. New innovative approaches to waste disposal require development and evaluation
under real world conditions. Finally, additional consideration must also be given to issues
beyond malaria control, such as role of PMRs in the wider health system and the legal and regu-
latory frameworks for in vitro diagnostics. A sustained scale up of RDTs in the private retail sec-
tor would require recognition from stakeholders, including regulatory bodies, that PMRs are a
viable alternative to public sector provision of quality care for uncomplicated malaria.
Limitations
This review employed a broad search strategy to identify all eligible studies where RDTs were
introduced in the private medicine retail sector. We did not include studies that included
Introducing malaria RDTs in private medicine retail outlets
PLOS ONE | DOI:10.1371/journal.pone.0173093 March 2, 2017 20 / 24
formal private health facilities such as clinics or hospitals. Since countries are making decisions
now about if or how RDTs can be introduced in PMRs, we decided that waiting for more stud-
ies to complete the publication process was deemed too much of a delay. While it is possible an
eligible but unpublished study could have been missed, this is unlikely given the involvement
of extensive contacts identified through the two convened stakeholder meetings in 2013 and
2015 and the large group of authors involved. Some studies did not have data on all the out-
comes assessed in the review. The mix of study designs (i.e. differences in intervention and
control arm design) and evaluation methods (i.e. mystery shopper or provider records) made
formal comparison of point estimates inappropriate. Differences in expectations of RDT posi-
tivity and patient demand for diagnosis across studies further limited comparability. The stud-
ies included in the review were all small scale trials or pilots with short durations. Most studies
evaluated outcomes at a single point in time, which may not be representative of embedded
and sustained effects. Finally, studies included in the review did not address the potential regu-
latory and policy barriers of introducing RDTs to PMRs. All of the studies, except in Myanmar,
were provided a waiver to perform RDTs.
Conclusions
Supporting the introduction of malaria rapid diagnostic testing in private medicine retail out-
lets has the potential to target antimalarial drugs more effectively. This review shows that a
range of private providers in different countries can incorporate RDTs into their practice,
although with varying degrees of uptake and influence on case management. This review sug-
gests investment in training and supervision may be beneficial to supporting RDT implemen-
tation. However, substantial gaps remain in the evidence for systems that will allow for RDT
implementation at scale.
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